ImmunityBio (IBRX) Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Is ASND or IBRX more profitable?

Ascendis Pharma A/S has a net margin of -130.33% compared to ImmunityBio's net margin of -8,016.83%.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-130.33%	N/A	-48.77%
ImmunityBio	-8,016.83%	N/A	-110.02%

Do insiders & institutionals believe in ASND or IBRX?

8.6% of ImmunityBio shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 83.4% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has better earnings and valuation, ASND or IBRX?

Ascendis Pharma A/S has higher revenue and earnings than ImmunityBio. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$327.43M	25.26	-$521.07M	-$8.08	-16.88
ImmunityBio	$7.33M	249.00	-$583.20M	-$0.92	-2.85

Which has more risk & volatility, ASND or IBRX?

Ascendis Pharma A/S has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Do analysts prefer ASND or IBRX?

Ascendis Pharma A/S presently has a consensus target price of $191.77, suggesting a potential upside of 40.61%. ImmunityBio has a consensus target price of $17.38, suggesting a potential upside of 563.17%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92
ImmunityBio	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the media favor ASND or IBRX?

In the previous week, Ascendis Pharma A/S had 10 more articles in the media than ImmunityBio. MarketBeat recorded 15 mentions for Ascendis Pharma A/S and 5 mentions for ImmunityBio. Ascendis Pharma A/S's average media sentiment score of 0.92 beat ImmunityBio's score of 0.28 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor ASND or IBRX?

Ascendis Pharma A/S received 433 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 66.52% of users gave Ascendis Pharma A/S an outperform vote while only 22.22% of users gave ImmunityBio an outperform vote.

Company	Underperform	Outperform
Ascendis Pharma A/S	Outperform Votes 439 66.52%	Underperform Votes 221 33.48%
ImmunityBio	Outperform Votes 6 22.22%	Underperform Votes 21 77.78%

Summary

Ascendis Pharma A/S and ImmunityBio tied by winning 9 of the 18 factors compared between the two stocks.